ArticlePloS one2025
Differences in the incidence of cirrhosis-associated complications between MASLD, MetALD and ALD among patients with decompensated liver cirrhosis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cardiometabolic Risk Factors Impair Recompensation and Survival in Alcohol-Associated Liver Disease.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026Observational
- Laboratory inflammation-nutrition index predicts mortality in MASLD/MetALD: evidence from a national cohort.International journal of surgery (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently, the new definition of steatotic liver disease (SLD) has been introduced, which not only differentiates MASLD (Metabolic Dysfunction-Associated steatotic liver disease) from alcohol-related steatotic liver disease (ALD), but also introduces the concept of metabolic and alcohol-related SLD (MetALD). However, potential differences of the new etiologies regarding the clinical phenotype of patients with advanced liver cirrhosis still remain undetermined. Therefore, we analyzed survival and the incidence of cirrhosis-related complications in SLD-patients with advanced liver cirrhosis.
methodsA number of 416 consecutive patients with MASLD, MetALD- and ALD-associated decompensated liver cirrhosis were investigated. Overall survival, infections, hepatic encephalopathy, portal-hypertensive bleeding, rehospitalization and development of hepatocellular carcinoma were retrospectively analyzed within one year of follow-up. Cox regression analyses were performed for survival, competing risk analyses for the cirrhosis-specific complications. MASLD was used as reference group.
resultsALD was associated with a lower risk of infections (HR = 0.55; p < 0.001) compared to MASLD. This remained significant after adjustment for age, sex, Model for End-Stage Liver Disease (MELD), serum-sodium, serum-cholinesterase, diabetes, body mass index and norfloxacin (HR = 0.59; p = 0.02) in the multivariable competing risk model. Notably, the incidence of infections in MetALD patients was in between both groups (MetALD: 68.7%, ALD: 56.1%, MASLD: 87.3%). However, there were no differences in survival (MetALD: HR = 1.03; p = 0.93; ALD: HR = 0.79; p = 0.49) and the other complications studied here.
conclusionThe risk of infections is increased in MASLD-associated cirrhosis compared to other SLD-phenotypes. Thus, the role of a metabolic risk profile should not be neglected even in patients with decompensated liver cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.